Next Article in Journal
Interventional and surgical management of abdominal compartment syndrome in severe acute pancreatitis
Previous Article in Journal
Immune factors in human embryo culture and their significance
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Tigecycline – how powerful is it in the fight against antibiotic-resistant bacteria?

1
Department of Biochemistry and Biophysics, Faculty of Natural Sciences, Vilnius University
2
Institute of Oncology, Vilnius University, 3Department of Microbiology, Kaunas University of Medicine, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2010, 46(4), 240; https://doi.org/10.3390/medicina46040033
Received: 28 May 2009 / Accepted: 6 April 2010 / Published: 11 April 2010
Tigecycline is a semisynthetic analogue of earlier tetracyclines and represents the first member of a novel class of antimicrobials – glycylcyclines – recently approved for clinical use. It is active against a broad range of gram-negative and gram-positive bacterial species including clinically important multidrug-resistant nosocomial and community-acquired bacterial pathogens. The exact molecular basis of tigecycline action is not clear at present, although similarly to the tetracyclines, it has been shown to inhibit the translation elongation step by binding to the ribosome 30S subunit and preventing aminoacylated tRNAs to accommodate in the ribosomal A site. Importantly, tigecycline overcomes the action of ribosomal protection proteins and is not a substrate for tetracycline efflux pumps of most bacteria – well-known and prevalent cellular mechanisms of microbial tetracycline resistance. The present review summarizes current knowledge on the molecular mechanism of the tigecycline action, antibacterial activity against various bacteria, clinical application, development of resistance to glycylcyclines.
Keywords: tigecycline; mechanism of action; in vitro and in vivo activity; resistance tigecycline; mechanism of action; in vitro and in vivo activity; resistance
MDPI and ACS Style

Šeputienė, V.; Povilonis, J.; Armalytė, J.; Sužiedėlis, K.; Pavilonis, A.; Sužiedėlienė, E. Tigecycline – how powerful is it in the fight against antibiotic-resistant bacteria? Medicina 2010, 46, 240.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop